Therapeutic musk antibodies

US11492401B2 · kind B2 · utility

Assignees

• NEW YORK UNIVERSITY · US
• ARGENX IIP BV · BE

Inventors

• Steven J. Burden · Boise, US
• Shohei Koide · Nagoya, JP
• Akiko Koide · New York, US
• Nadia LELOUP · New York, US
• Julien Oury · New York, US
• Karen Silence · Overijse, BE
• Roeland Vanhauwaert · Wondelgem, BE
• Christophe Blanchetot · Laarne, BE

Key dates

• Filing date: Dec 30, 2021
• Grant date: Nov 8, 2022
• Expiry date: Dec 30, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to antibody-based molecules, including full-length antibodies, antigen-binding domains thereof, and antibody derivatives that are capable of binding to and activating human muscle-specific tyrosine protein kinase (MuSK). The present invention further discloses methods of treating neuromuscular conditions using the aforementioned MuSK antibodies.